Apogee Therapeutics reported its full‑year 2025 financial results, posting a net loss of $255.8 million and earnings per share of $‑1.03, a $0.05 beat over the consensus estimate of $‑1.08. Revenue remained at $0.0 million, reflecting the company’s pre‑revenue status. Cash and cash equivalents stood at $902.9 million as of December 31 2025, giving the company a runway that extends into the second half of 2028.
The net loss widened from $182.1 million in 2024, while research and development expenses rose to $214.7 million from $167.9 million, and general‑and‑administrative costs increased to $70.9 million from $49.0 million. Despite the higher operating outlays, Apogee’s actual costs were lower than analysts had anticipated, allowing the company to beat the EPS estimate by $0.05 per share.
The substantial cash balance provides the company with the flexibility to fund its clinical pipeline without immediate financing pressure. The extended runway supports the planned execution of multiple late‑stage studies and the eventual launch of its lead candidate, zumilokibart (APG777).
Key clinical milestones for 2026 include the 52‑week maintenance readout for APG777 expected in March, the Part B 16‑week readout in the second quarter, and the initiation of a Phase 3 trial in the second half of 2026. A head‑to‑head trial of APG279 versus Dupixent is also scheduled, with interim data anticipated in the second half of 2026.
"In the last 12 months we made meaningful progress across our pipeline, including advancing zumilokibart with positive APEX Phase 2 Part A results, as well as proof‑of‑concept data from our Phase 1b trial in asthma. We are now focused on proving out the potential of zumilokibart in AD with the APEX Phase 2 Part A 52‑week maintenance readout expected in March, followed by the APEX Phase 2 Part B dose optimization readout expected in the second quarter and Phase 3 initiation targeted by year end. Later this year, we plan to provide additional details on development for expansion indications including asthma and EoE, further advancing our vision for zumilokibart as a pipeline‑in‑a‑product."
"We achieved significant progress across our pipeline in 2024 and are well‑positioned to continue executing rapidly on our mission to bring transformative, potentially best‑in‑class therapies to patients with I&I diseases. We kicked off 2025 by over‑enrolling Part A and dosing the first patient in the Part B portion of our Phase 2 APEX clinical trial for APG777 in AD, well ahead of schedule and we are on track for our critical 16‑week readout for APG777 in mid‑2025."
"2025 was a foundational year for Apogee, setting the stage for a potentially transformational 2026 as we plan to deliver multiple significant clinical data readouts for our monotherapy and combination programs and enter Phase 3 development. With today's positive readout in patients with mild‑to‑moderate asthma, we are excited to advance zumilokibart in asthma and seek to further derisk its pipeline‑in‑a‑product potential. We look forward to reporting three clinical readouts for atopic dermatitis in 2026."
Apogee’s management signals confidence in its pipeline and financial stewardship. The company plans to report three atopic dermatitis readouts in 2026, expand indications for APG777 into asthma and eosinophilic esophagitis, and continue to pursue Phase 3 development. The combination of a robust cash position, a clear clinical roadmap, and a focused strategy to differentiate its lead candidate positions Apogee for potential future product launches in the coming years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.